Nasus Pharma Ltd
Datakwaliteit: 100%
NSRX
NYSE
Manufacturing
Chemicals
€ 2,26
▼
€ 0,08
(-3,42%)
Marktkapitalisatie: 26,47 M
Prijs
€ 2,26
Marktkapitalisatie
26,47 M
Dagbereik
€ 2,25 — € 2,36
52-Weeksbereik
€ 1,98 — € 9,99
Volume
16.404
Openen € 2,32
50D / 200D Gem.
€ 4,48
49,56% below
50D / 200D Gem.
€ 6,57
65,61% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -4,93 M
Capital efficient — spends only 0,00% of revenue on capex
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-211,56%
Onder sectorgemiddelde (-53,47%)
ROIC-136,37%
Net Margin-0,47%
Op. Margin-0,40%
Veiligheid
Debt / Equity
N/A
Current Ratio0,06
Interest Coverage-62,87
Waardering
PE (TTM)
-4,52
Onder sectorgemiddelde (-1,47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -4,5 | -1,5 |
| P/B | — | 1,6 |
| ROE % | -211,6 | -53,5 |
| Net Margin % | -0,5 | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 1,24 B | Net Income (TTM) | -5,86 M |
| ROE | -211,56% | ROA | -117,03% |
| Gross Margin | N/A | Operating Margin | -0,40% |
| Net Margin | -0,47% | Free Cash Flow (TTM) | -4,93 M |
| ROIC | -136,37% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0,06 |
| Interest Coverage | -62,87 | Asset Turnover | 246,80 |
| Working Capital | -4,66 M | Tangible Book Value | -4,31 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -4,52 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | 0,02 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -18,63% | ||
| Market Cap | 26,47 M | Enterprise Value | 26,26 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,72 | Revenue / Share | 105,46 |
| FCF / Share | -0,42 | OCF / Share | -0,42 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0,00% | FCF Conversion | 84,22% |
| SBC-Adj. FCF | -5,38 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 |
|---|---|
| Revenue | 1,24 B |
| Net Income | -5,86 M |
| EPS (Diluted) | -0,72 |
| Gross Profit | — |
| Operating Income | -4,90 M |
| EBITDA | — |
| R&D Expenses | 2,24 M |
| SG&A Expenses | — |
| D&A | — |
| Interest Expense | -78.000,0 |
| Income Tax | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 |
|---|---|
| Total Assets | 5,00 M |
| Total Liabilities | 2,24 M |
| Shareholders' Equity | 2,77 M |
| Total Debt | — |
| Cash & Equivalents | 1,24 M |
| Current Assets | 4,86 M |
| Current Liabilities | 2,16 M |
{"event":"ticker_viewed","properties":{"ticker":"NSRX","listing_kind":"stock","pathname":"/stocks/nsrx","exchange":"NYSE","country":"US"}}